Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Infect Disord Drug Targets ; 2022 Apr 22.
Article in English | MEDLINE | ID: covidwho-2114908

ABSTRACT

Backgrounds & Aim: Coronavirus disease 2019 (Covid-19) is a severe acute respiratory syndrome caused by Coronavirus 2. Knowledge of the fate of infection and risk factors among health care workers are essential to enforce special infection control measures. We aimed to determine the percentage of COVID-19 infection and risk factors associated and predictors of COVID-19 among health care workers in Assiut University Hospital. METHODS: A cross-sectional study that included one hundred health care workers with confirmed by PCR to be COVID-19 cases admitted in Assiut university hospital over six months between May 2020 and November 2020. All participants subjected to thorough history taking and full clinical examination as well as investigations. RESULTS: Out of the 100 HCWs enrolled in study, 52% were males, 26% were obese, and 68% were doctors & 38% from medical department. Fourteen percentage of healthcare workers were admitted to ICU, of them 93% cured. The predictors for severity of cases were being a doctor OR (6.804) P=0.037, old age OR (1.179) P=0.000 & hospital stay OR (0.838) P=0.015. CONCLUSION: Health care workers are at-risk for severe COVID-19 infection. Being a doctor, old age, and duration of hospitalization were the predictors for severity of cases of health care workers.

2.
Clin Appl Thromb Hemost ; 28: 10760296221107889, 2022.
Article in English | MEDLINE | ID: covidwho-1892132

ABSTRACT

AIM: Our study's objectives were to study the clinical and laboratory characteristics that may serve as biomarkers for predicting disease severity, IL-10 levels, and frequencies of different T cell subsets in comorbid COVID-19 patients. METHODS: Sixty-two hospitalized COVID-19 patients with comorbidities were assessed clinically and radiologically. Blood samples were collected to assess the T lymphocyte subsets by flow cytometry and IL-10 levels by ELISA. RESULTS: The most common comorbidities observed in COVID-19 patients were diabetes mellitus (DM), hypertension, and malignancies. Common symptoms and signs included fever, cough, dyspnea, fatigue, myalgia, and sore throat. CRP, ferritin, D dimer, LDH, urea, creatinine, and direct bilirubin were significantly increased in patients than controls. Lymphocyte count and CD4+ and CD8+ T-cells were significantly decreased in comorbid COVID-19 patients, and CD25 and CD45RA expression were increased. CD4+ and CD8+ regulatory T cells (Tregs) and IL-10 levels were significantly decreased in patients. CONCLUSIONS: Many parameters were found to be predictive of severity in the comorbid patients in our study. Significant reductions in the levels and activation of CD4+ and CD8+ T-cells were found. In addition, CD4+ and CD8+ Tregs were significant decreased in patients, probably pointing to a prominent role of CD8+ Tregs in dampening CD4+ T-cell activation.


Subject(s)
COVID-19 , T-Lymphocyte Subsets , CD8-Positive T-Lymphocytes , COVID-19/immunology , Comorbidity , Humans , Interleukin-10 , Lymphocyte Count , T-Lymphocyte Subsets/cytology , T-Lymphocyte Subsets/immunology , T-Lymphocytes, Regulatory
3.
J Med Virol ; 93(10): 5833-5838, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1432414

ABSTRACT

Researchers around the world are working at record speed to find the best ways to treat and prevent coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy of ivermectin for the treatment of hospitalized mild to moderate COVID-19 infected patients. This was a randomized open-label controlled study that included 164 patients with COVID-19. Patients were randomized into two groups where Group 1 (Ivermectin group) included patients who received ivermectin 12 mg once daily for 3 days with standard care and Group 2 (control group) included patients who received standard protocol of treatment alone for 14 days. The main outcomes were mortality, the length of hospital stay, and the need for mechanical ventilation. All patients were followed up for 1 month. Overall, 82 individuals were randomized to receive ivermectin plus standard of care and 82 to receive standard of care alone. Patients in the ivermectin group had a shorter length of hospital stay (8.82 ± 4.94 days) than the control group (10.97 ± 5.28 days), but this was not statistically significant (p = 0.085). Three patients (3.7%) in each group required mechanical ventilation (p = 1.00). The death rate was three patients in the ivermectin group (3.7%) versus four patients (4.9%) in the control group without any significant difference between the two groups (p = 1.00). Although there was no statistically significant difference in any endpoints by ivermectin doses (12 mg/day for 3 days); there was an observed trend to reducing hospital stay in the ivermectin-treated group.


Subject(s)
Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , Ivermectin/therapeutic use , Adult , Aged , COVID-19/diagnosis , COVID-19/mortality , Egypt/epidemiology , Female , Humans , Length of Stay , Male , Middle Aged , Respiration, Artificial , SARS-CoV-2/drug effects , Treatment Outcome
4.
Curr Med Imaging ; 17(12): 1473-1480, 2021.
Article in English | MEDLINE | ID: covidwho-1221872

ABSTRACT

BACKGROUND AND AIMS: In the midst of this pandemic, planning the prioritization of hospital admissions for patients affected with COVID-19 should be of prime concern, particularly in healthcare settings with limited resources. Thus, in this study, we aimed to develop a novel approach to triage COVID-19 patients and attempt to prioritize their hospital admission using Lung Ultrasonography (LUS). The efficacy of LUS in triaging suspected COVID-19 patients and assessing the severity of COVID-19 pneumonia was evaluated; the findings were then compared with those obtained by chest computed tomography (CT). METHODS: This multicenter, cross-sectional study comprised 243 COVID-19 patients who presented to the emergency department in 3 major university hospitals in Egypt. LUS was performed by an experienced emergency or chest physician, according to the local protocol of each hospital. Demographic, clinical, and laboratory data were then collected from each patient. Each patient was subjected to chest CT scans and LUS. RESULTS: The mean age of the 243 patients was 46.7 ± 10.4 years. Ground-glass opacity, subpleural consolidation, translobar consolidation, and crazy paving were reported in the chest CT scans of 54.3%, 15.2%, 11.1%, and 8.6% of the patients, respectively. B-line artifacts were observed in 81.1% of the patients (confluent pattern, 18.9%). The LUS findings completely coincided with the CT findings (Kappa agreement value, 0.77) in 197 patients (81.1%) and offered a diagnostic sensitivity of 74%, diagnostic specificity of 97.9%, positive predictive value of 90.2%, and negative predictive value of 93.6% for the COVID-19 patients. Following the addition of O2 saturation to the lung imaging findings, the ultrasound method was able to demonstrate 100% sensitivity and specificity in accurately differentiating between severe and non-severe lung diseases. CONCLUSION: LUS with oxygen saturation might prove to be effective in prioritizing the hospital admission of COVID-19 patients, particularly in healthcare settings with limited resources.


Subject(s)
COVID-19 , Clinical Decision-Making , Hospitalization , Ultrasonography , Adult , COVID-19/diagnosis , Cross-Sectional Studies , Developing Countries , Humans , Lung/diagnostic imaging , Middle Aged , Oxygen Saturation
SELECTION OF CITATIONS
SEARCH DETAIL